30 August 2018, 4:49pm
Richard Hoskins, Co-founder, Kin Capital discusses the relative lack of awareness around Venture Capital Trusts. See an extract of the article below, full article available on FT Adviser here
Half of high earning individuals have never heard of venture capital trusts (VCTs), despite the tax breaks associated with those products being of most benefit to those paying substantial amounts of income tax. Albion Capital, a venture capital trust provider, surveyed 250 individuals with annual incomes above £125,000 in May, and found 50 per cent had not heard of the products, while 76 per cent of those surveyed had never invested in VCTs. A third of those surveyed said they would consider investing in the products if they were recommended to do so by a financial adviser.
The number one reason people did not currently invest in the products was a lack of knowledge, it emerged. Venture Capital Trusts (VCTs) are investment funds listed on a recognised stock exchange that invest in unquoted companies. Investors who hold the shares for five years receive a 30 per cent income tax break, while any income earned from the investments in the trust is exempt from income tax. The Treasury changed the rules last year around the types of companies into which VCT managers deploy capital, as it wanted the products to focus on riskier assets, saying they had not always been used as intended.
Will Fraser Allen, deputy managing partner at Albion Capital, said: “VCTs have entered the mainstream in recent years as a steady erosion of other tax efficient means of saving and investing has boosted their popularity. “We were surprised by these findings, which suggest a relative lack of knowledge of VCTs’ qualities and indicate more work needs to be done to raise awareness of the tax benefits, income potential and opportunity to support exciting UK growth businesses.”
But Richard Hoskins, who co-founded Kin Capital, a firm engaged in the marketing of VCTs, said the relative lack of awareness was not a surprise to him. He said:
“Not enough advisers are fully aware of VCTs. There is a perception they are very, very high risk, but while they are never going to be a product for widows and orphans, if you buy a range of VCTs then the risks are lower.”
He added concerns over the implications for their indemnity insurance may be another reason advisers are reluctant to recommend VCTs, while the fact an investor in the products must remain invested for five years imposes a “discipline” on investors which some may find unappealing.
To read the full article please see here.
Join Kin Capital and our 2018/19 fund managers in London, Manchester and Birmingham. Read more...
EIS funded businesses First Light Fusion, Cytora, OxSyBio and Paddle are featured on the list. Read more...
Portfolio company Transcend Packaging received EIS funding in Spring 2018, with an aim to replace single use plastics. Read more...
New Year, New Office! We’ve settled into the fast paced area of King’s Cross! Our new address is: Kin Capital, East… twitter.com/i/web/status/1…
"The government is actively assisting in that transition with its support of the venture capital ecosystem" - Tom H… twitter.com/i/web/status/1…
LAUNCHING SOON - technology & e-commerce EIS fund, offering 100% tax relief, from industry leading venture capitalist Fuel Ventures More >
OFFER OPEN - The most popular growth EIS Fund for the last three tax years, according to figures published by independent commentator Tax Efficient Review. More >
OFFER OPEN - invest in growth businesses within the Leisure & Hospitality market through Imbiba Leisure EIS More >
OFFER OPEN - invest in a portfolio of primarily early stage SEIS qualifying companies across different sectors including digital technology, life sciences and consumer goods More >
OFFER OPEN - invest in sustainable energy companies eligible for Business Relief (BR) through Guinness Sustainable Infrastructure Service More >
OFFER OPEN - invest in a portfolio of primarily early stage EIS qualifying companies across different sectors including digital technology, life sciences and consumer goods More >